(MedPage Today) — The FDA approved lurbinectedin (Zepzelca) plus either atezolizumab (Tecentriq) or atezolizumab and hyaluronidase (Tecentriq Hybreza) as first-line maintenance therapy for extensive-stage small cell lung cancer, the agency announced…
Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/117793
Author :
Publish date : 2025-10-03 19:18:00
Copyright for syndicated content belongs to the linked Source.
